Literature DB >> 31368147

Measuring the impact of pharmacovigilance activities, challenging but important.

Florence van Hunsel1, Helga Gardarsdottir2, Anthonius de Boer2,3, Agnes Kant1.   

Abstract

Keywords:  impact; pharmacovigilance; risk minimisation

Mesh：

Year:  2019        PMID： 31368147      PMCID： PMC6783581          DOI： 10.1111/bcp.14042

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  Channeling bias in the interpretation of drug effects.

Authors:  H Petri; J Urquhart
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

2.  Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs.

Authors:  Robert J Valuck; Anne M Libby; Heather D Orton; Elaine H Morrato; Richard Allen; Ross J Baldessarini
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

Review 3.  Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.

Authors:  Anjan Kumar Banerjee; Inge M Zomerdijk; Stella Wooder; Simon Ingate; Stephen J Mayall
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

4.  A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.

Authors:  Annalisa Rubino; Esther Artime
Journal:  Expert Opin Drug Saf       Date:  2017-06-07       Impact factor: 4.250

5.  The use of complementary and alternative medicines during breastfeeding: results from the Herbal supplements in Breastfeeding InvesTigation (HaBIT) study.

Authors:  Alessandra Bettiol; Niccolò Lombardi; Ettore Marconi; Giada Crescioli; Roberto Bonaiuti; Valentina Maggini; Eugenia Gallo; Alessandro Mugelli; Fabio Firenzuoli; Claudia Ravaldi; Alfredo Vannacci
Journal:  Br J Clin Pharmacol       Date:  2018-07-03       Impact factor: 4.335

6.  Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems.

Authors:  H G Leufkens; J Urquhart; B H Stricker; A Bakker; H Petri
Journal:  J Epidemiol Community Health       Date:  1992-08       Impact factor: 3.710

7.  Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.

Authors:  Sieta T de Vries; Maartje J M van der Sar; Anna Marie Coleman; Yvette Escudero; Alfonso Rodríguez Pascual; Miguel-Ángel Maciá Martínez; Amelia Cupelli; Ilaria Baldelli; Ivana Šipić; Adriana Andrić; Line Michan; Petra Denig; Peter G M Mol
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

Review 8.  Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulators.

Authors:  Priya Bahri; Mireia Castillon Melero
Journal:  Br J Clin Pharmacol       Date:  2018-05-31       Impact factor: 4.335

9.  Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.

Authors:  Thomas Goedecke; Daniel R Morales; Alexandra Pacurariu; Xavier Kurz
Journal:  Br J Clin Pharmacol       Date:  2017-12-20       Impact factor: 4.335

10.  Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.

Authors:  Alexandra Pacurariu; Kelly Plueschke; Patricia McGettigan; Daniel R Morales; Jim Slattery; Dagmar Vogl; Thomas Goedecke; Xavier Kurz; Alison Cave
Journal:  BMJ Open       Date:  2018-09-05       Impact factor: 2.692
View more
  4 in total

1.  Effect of pharmaceutical regulatory policy on health impact.

Authors:  Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2020-06-14       Impact factor: 4.335

2.  The effect of clinical pharmacists' intervention in adverse drug reaction reporting: a retrospective analysis with a 9-year interrupted time series.

Authors:  Tianwei Lan; Hua Wang; Xin Li; Hang Yin; Dan Shao; Yueyao Jiang; Qian Yu
Journal:  BMC Health Serv Res       Date:  2022-07-19       Impact factor: 2.908

3.  Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.

Authors:  Florence van Hunsel; Laura Peters; Helga Gardarsdottir; Agnes Kant
Journal:  Drug Saf       Date:  2021-02-19       Impact factor: 5.606

4.  Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).

Authors:  Priya Bahri; Daniel R Morales; Adrien Inoubli; Jean-Michel Dogné; Sabine M J M Straus
Journal:  Drug Saf       Date:  2020-10-30       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.